Other Clinical Trial - Nimotuzumab for Recurrent Nasopharyngeal Carcinoma

Status Recruiting

Clinical Trial Summary

The study assessed the clinical efficacy, and safety of the combination of Nimotuzumab administered concomitantly with intensity modulated radiation therapy(IMRT) in patients with recurrent nasopharyngeal cancer.

Clinical Trial Description

The clinical efficacy of Nimotuzumab combined with radiotherapy has been shown in advanced nasopharyngeal cancer, which was significantly higher than radiotherapy alone. The efficacy of radiotherapy combined with Nimotuzumab has not been confirmed in recurrent nasopharyngeal cancer.In this study, Phase II clinical trials were performed. The patients were treated with Nimotuzumab which were used concurrently with IMRT. The efficacy and toxicity will be assessed. ;

Study Design

Related Conditions & MeSH terms

Carcinoma
Nasopharyngeal Neoplasms
Recurrent Nasopharyngeal Carcinoma

Clinical Trial Details

NCT number	NCT03666221
Study type	Interventional
Source	Fujian Cancer Hospital
Contact	SHAOJUN LIN, Dr.
Phone	0591-62752225
Email	linshaojun@yeah.net
Status	Recruiting
Phase	Phase 2
Start date	November 1, 2014
Completion date	November 1, 2022

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT06010095` - Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer	Phase 2
Recruiting	`NCT03639467` - Study of Anlotinib Combined With Gemcitabine/Cisplatin in Advanced Nasopharyngeal Carcinoma	Phase 1/Phase 2
Recruiting	`NCT06029270` - Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer	Phase 2
Recruiting	`NCT05350891` - Transnasal Endoscopic Surgery Combined With Adjuvant Immunotherapy for Recurrent NPC	Phase 2
Active, not recruiting	`NCT04586088` - Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure	Phase 2
Active, not recruiting	`NCT04405622` - Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma.	Phase 2
Not yet recruiting	`NCT04215510` - Early Recurrent Nasopharyngeal Cancer: the Effect of Surgery vs IMRT	Phase 3
Recruiting	`NCT03907826` - PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients	Phase 3
Recruiting	`NCT03930498` - Programmed Death-1 (PD-1) Antibody Combined With Chemoradiotherapy in High-risk Recurrent Nasopharyngeal Carcinoma	Phase 2
Recruiting	`NCT04376866` - Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma	Phase 3
Not yet recruiting	`NCT05432219` - A Transoral Retropterygoid Approach to Resect Recurrent Nasopharyngeal Carcinoma	N/A
Recruiting	`NCT04425265` - Plasma Radiofrequency Ablation at Low Temperature Versus Electrocautery Block Resection at High Frequency for Localized Recurrent Nasopharyngeal Carcinoma	N/A
Not yet recruiting	`NCT03689556` - Examine the Prognostic Role of FLT PET/CT for Patients With LR-NPC Treated by Carbon Ion Therapy
Not yet recruiting	`NCT03210389` - A Clinical Trial of Chemotherapy With Lobaplatin and 5-FU in Recurrent Local or Distant Advanced NPC.	Phase 2
Completed	`NCT01392235` - Famitinib in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma (NPC)	Phase 2
Completed	`NCT01370070` - MK-2206 in Recurrent Nasopharyngeal Carcinoma	Phase 2
Not yet recruiting	`NCT06235203` - Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC	Phase 3
Not yet recruiting	`NCT06228079` - Adjuvant vs Surgery Only in Early-stage Recurrent NPC	Phase 3
Terminated	`NCT04458909` - Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer	Phase 3
Withdrawn	`NCT04231864` - Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer	Phase 2